Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
TELA Bio ( (TELA) ) has provided an announcement.
On August 11, 2025, TELA Bio reported its financial results for the second quarter of 2025, highlighting a revenue of $20.2 million, marking a 26% increase from the previous year. The company experienced increased demand for its OviTex and OviTex PRS products and launched OviTex Inguinal in Europe. Despite a net loss of $9.9 million, TELA Bio reiterated its full-year revenue guidance, reflecting confidence in its growth trajectory. The appointment of Jeffrey Blizard as President is expected to strengthen the company’s commercial leadership and drive sales execution.
The most recent analyst rating on (TELA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on TELA Bio stock, see the TELA Stock Forecast page.
Spark’s Take on TELA Stock
According to Spark, TipRanks’ AI Analyst, TELA is a Neutral.
TELA Bio’s strong revenue growth and strategic changes are promising, particularly in international markets. However, profitability challenges, high leverage, and negative cash flows offset these strengths. The technical indicators suggest caution, and the valuation is unattractive due to ongoing losses.
To see Spark’s full report on TELA stock, click here.
More about TELA Bio
TELA Bio, Inc. is a commercial-stage medical technology company specializing in innovative soft-tissue reconstruction solutions. The company focuses on optimizing clinical outcomes by leveraging the patient’s natural healing response and minimizing long-term exposure to synthetic materials. TELA Bio aims to provide surgeons with advanced and economically effective solutions for soft-tissue reconstruction.
Average Trading Volume: 111,930
Technical Sentiment Signal: Sell
Current Market Cap: $68.03M
For detailed information about TELA stock, go to TipRanks’ Stock Analysis page.